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Background: On the basis of previous findings on random individuals, we hypothesized a preferential association of CF causing mutations
with the M allele of the M470V polymorphic site of the CFTR gene.
Methods: We have determined the M/V-CF mutation haplotype in a series of 201 North East Italian and 73 Czech CF patients who were not
F508del homozygotes, as F508del was already known to be fully associated with the M allele.
Results: Out of 358 not F508del CF genes, 84 carried the V allele and 274 the less common M allele. In the N-E Italian population, MM
subjects have a risk of carrying a CF causing mutation 6.9 greater than VV subjects when F508del is excluded and 15.4 when F508del is
included. In the Czech population a similar, although less pronounced, association is observed.
Conclusions: Besides the possible biological significance of this association, the possibility of exploiting it for a pilot screening program has
been explored in a local North East Italian population for which CF patients were characterized for their CF mutation. General M470V
genotyping followed by common CF mutation screening limited to couples in which each partner carries at least one M allele would need
testing only 39% of the couples, which contribute 89% of the total risk, with a cost benefit.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: M470V polymorphism; Haplotype; CFTR; CF risk
21. Introduction
Cystic Fibrosis (CF) is the most common severe
autosomal recessive disease among Europeans (ca. 1/
2500). To date several hundred CF-causing mutations with
very different frequencies in different populations have been
described. However, in all European countries, the com-
bined (=total) frequency of the CF-causing alleles is 0.02
[1]. Therefore, the proportion of the Fat risk_ couples1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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rable with the prevalence of Down syndrome for which
screening procedures are commonly carried out. Thus,
considering the severity of the CF disease and its expected
prevalence, a general prevention program would be justified.
Since no simple and reliable method to identify at the
phenotypic level the heterozygotes for CF alleles is
available, only the more challenging method of mutation
detection at the DNA level has to be used. CFTR is a large
gene [2], therefore, if the CF alleles were represented by
many different extremely rare alleles, even retrospective
molecular genetic analysis would be tremendously difficult.
Fortunately, this is not the case because a single CF allele,s 6 (2007) 15 – 22ed by Elsevier B.V. All rights reserved.
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mutations, about 90 and 50% in Northern and Southern
Europe, respectively [1]. Clearly then, for Northern Europe,
a screening restricted to this CF allele would be effective
enough for prospective counselling, whereas this strategy
would be far from sufficient for Southern Europe. In this
case such a goal would require a screening of the several
tens common CF mutations that account for approximately
85% of all the CF mutations of the area [1], an extensive
task in cost-benefit terms.
It has been shown that the variability of European random
CFTR genes is almost completely restricted to theCFTR genes
carrying the M allele of the M470V polymorphic site [3]. This
finding has been tentatively interpreted as an example of
sweeping selection caused by the birth of an advantageous
mutation in a V gene; from that moment onwards this
hypothetical gene would have rapidly spread [3] while
accumulating some variability through recombination and
recent mutational events. This Fallele-restricted_ variability has
been reported also for some CF mutations, and particularly for
F508del (hereafter sometimes designated simply F mutation),
in various European countries [4–6], thus allowing one to
subdivide the general population into classes of individuals
having a different risk of being carriers of a CF mutation. We
decided to quantify this differential risk in one Southern
European country, and to test this finding in a second Central
European country, by determining the frequency of the M and
the V alleles in a sample of NonF508del CF genes (hereafter
designated as NonF CF mutations).
Indirect CF prevention through haplotype analysis has
been utilized since long (see, for example, Ref. [7]); here we
have explored the possibility of utilizing a single polymor-
phism instead of a complex haplotype.2. Materials and methods
2.1. The sample
Both the Italian and the Czech samples consisted of CF
patients not homozygous for F508del (201 Italians and 73
Czechs) and of their parents. The Italian patients (almost
exclusively from the North-Eastern Italy regions Veneto
and Trentino Alto Adige) were selected from a cohort ofNotes to Table 1:
(1)It cannot be excluded that very few of these mutations actually are not CF
overall results to an appreciable extent.
(2)CF mutations which, when tested, were examined in all the specimens.
(3)The distance is from the 3’ end of the deletion.
(4)CF mutations not searched for in all individuals.
(5)In one case this mutation has been found in cis with the R1070Q variant.
(6)DEFINED=mutations identified AND assigned either to M or to V allele;
tested.
-=mutations screened in all specimens in both populations.
0=CF mutations not searched for in all the Italian specimens.
The grey boxes refer to CF mutations found both in the M and the V allele268 patients: 67 F/F homozygotes; 130 F/NonF and 71
NonF/NonF (clearly in HW equilibrium); equivalent to
264 F and 272 NonF genes, in good agreement with the
1:1 F vs NonF subdivision of the CF alleles in this area
[1]. The Czech patients were selected from a cohort of
247 patients among which the frequency of the F mutation
was 0.719. All patients had typical clinical findings of
pulmonary and/or gastrointestinal disease together with
sweat chloride levels greater than 60 mEq/l.
2.2. Molecular genetics analysis
The selected 274 CF patients and their parents have been
specifically examined for the M470V polymorphism as
previously described [8]. The CF mutations have been
searched for as follows:
2.2.1. Italian sample
All the 201 CF patients were analyzed [9] for F508del
and for 15 other CF mutations (1st group in Table 1).
Thirty one additional CF mutations (ref. nos. 5 and 6 of
the 1st group and all those of the 2nd group in Table 1),
instead, have been detected not examining all samples.
The CF mutation was not identified in 39 genes and not
assigned to M or V allele in 4 cases. These 43 CF genes are
here reported as Fnot defined_.
2.2.2. Czech sample
All the 73 CF patients were examined with the ‘‘Roche
molecular system kit’’ which detects 38 CF mutations. The
specimens negative with this Fstandard_ analysis were
examined by DGGE [10]. The 13 Fnot defined_ CF
mutations refer to not identified CF mutations.
2.3. Classification of the M/V-CF haplotypes
For the present study a NonF CF mutation is informative
if it has been unambiguously assigned either to the M470 or
to the V470 CFTR allele. Such assignment has not been
possible for 36 CF mutations of the Italian sample (18 CF
M/V patients with both parents M/V heterozygotes), and 6
CF mutations of the Czech sample (3 CF M/V patients). The
simple exclusion of these CF mutations from the sample
would have preferentially affected the CF mutations-causing mutations. Even if this were the case it would not affect the
NOT DEFINED=mutations not identified OR not assigned; n.t.=not
s.
Table 1
A list of the CF mutations found in the two samples and their association with the M or the V allele
B.M. Ciminelli et al. / Journal of Cystic Fibrosis 6 (2007) 15–22 17
Table 3
Absolute frequencies of the 6 possible couples in the Italian sample of 71
couples of parents of NonF/NonF CF patients
Couples Exp1 Obs Exp2
MMMM 1.6 10 7.0
MMMV 9.9 24 25.4
MMVV 8.0 5 5.1
MVMV 15.9 25 23.2
MVVV 25.4 7 9.4
VVVV 10.2 0 0.9
m23df =93.9 m
2
2df =3.0
P0 P=0.22
For each type of couple the expected absolute frequencies were computed
by multiplying its expected relative frequency in the general population by
71 (total number of couples of the sample) and by 1 (uniform risk: Exp1) or
by the here estimated specific relative risk (Exp2, see text).
B.M. Ciminelli et al. / Journal of Cystic Fibrosis 6 (2007) 15–2218associated with the V allele, thus causing a highly biased
underestimate of the CF-V haplotype frequency. Therefore
we decided not to discard them. Sixteen of the Italian
patients and the three Czech patients were heterozygotes for
a CF mutation always found on the M allele in the specific
population under study and another CF mutation, thus the
latter was assigned to the V allele. In particular, 12 Italian
and the 3 Czech CF patients carried the F508del (that has
been unambiguously assigned to the M allele 118/118 and
57/57 times in the present two samples, respectively, in
agreement with previous reports); 1 carried the 2183AAYG
(21/21); 1 carried the I507del (7/7), 1 carried the 1717-
1GYA (20/20) and 1 carried the G542X (19/19). The CF
mutations of the remaining two Italian patients have been
assigned to the class of the Fnot defined_ CF mutations.3. Results
3.1. The Italian sample
Table 1 reports the 47 CF mutations found in the present
survey. Twenty five were associated only with the M allele,
19 (all uncommon) only with the V allele and 3 with both.
The here observed frequencies of the first group CF
mutations only can be considered reliable estimates of their
relative contribution to the overall CF mutation frequency,
whereas the frequencies of the F508del and of all the CF
mutations of the second group are underestimates.Table 2
Frequencies of the M and the V alleles in (a) the Italian and (b) the Czech
CF samples
CF mutations n M V
Obs Expa Obs Expa
(a)
F508del 130 130 50.1 0 79.9
1.00 0.385 0.00 0.615
Other
Definedb 229 196 88.2 33 140.8
0.856 0.385 0.144 0.615
Not definedb 43 25 16.6 18 26.4
0.581 0.385 0.419 0.615
Total 272 221 104.7 51 167.3
0.813 0.385 0.187 0.615
(b)
F508del 60 60 23.1 0 36.9
1.00 0.385 0.00 0.615
Other
Definedb 73 48 28.1 25 44.9
0.658 0.385 0.342 0.615
Not definedb 13 5 5.0 8 8.0
0.385 0.385 0.615 0.615
Total 86 53 33.1 33 52.9
0.616 0.385 0.384 0.615
a computed by utilizing the frequencies of the M and V alleles in Europe
(0.385 and 0.615, respectively: see Modiano et al., Ref [11])
b see caption (6) of Table 1.The complete association of the F508del with the M
allele is confirmed.
Among the 229 defined CF mutations other than F508del
196 (=0.856) turned out to be associated with the M allele
and only 33 (=0.144) with the V allele (Table 2a).
For the 43 not defined CF mutations (the least
common ones) the degree of the preferential association
with the M allele (0.581, instead of 0.385, which is the
frequency of this allele in Europe, ref. 11; see Table 2a),
though statistically significant (P0.01), is fourfold less
than that found among the defined CF mutations (0.581/
0.419 vs 0.856/0.144; see Table 2a). This result suggests
that the (rarest) not defined CF mutations are largely due
to recent mutational events which should have occurred
randomly on the CFTR genes (see Introduction).
On the whole, among the 272 NonF CF mutations which
cumulative frequency in the general population is 0.01
(namely half of 0.02), 221 (=0.813) were found among the
CFTR-M genes (which frequency is 0.385). Thus, in the
random population, the overall frequency of the haplotypes
M-NonF CF mutations is 0.8130.01=0.0081. Therefore,
in a sample of CFTR genes carrying the M allele the
frequency of the NonF CF mutations is 0.0081 /
0.385=0.0211. The complementary frequency of the hap-
lotype V-NonF CF mutations is 0.1870.01=0.0019,
which corresponds to a frequency within the V CFTR
alleles of 0.0019 /0.615=0.0031. The strong association of
the CF mutations with the M allele has been quantitatively
proved also at the couple level (Table 3). Clearly, since the
F508del mutation is only associated with the M allele, the
overall frequency of the CF alleles among this allele is
(0.01+0.0081) /0.385=0.047.
3.2. The Czech sample
It consists of 60 F508del and 86 NonF CF alleles (73
defined and 13 not defined) (Tables 1 and 2b). Also in
this case the frequency of the F allele and of the CF
mutations of the second group are to be considered
underestimates. A preferential association of the NonF CF
B.M. Ciminelli et al. / Journal of Cystic Fibrosis 6 (2007) 15–22 19mutations with the M allele is observed, though to a
much lesser extent than in the Italian sample (0.616 vs
0.813: Table 2b vs Table 2a). This is mainly due to the
occurrence at a relatively high frequency in this
population, of the CFTRdele2,3 CF mutation (5.5% of
the CF alleles, ref. 12), which is always associated with
the V allele.4. Discussion
A high heterogeneity among different European popula-
tions for CF alleles is known [12], and it has been confirmed
by present data. In particular, out of 12 NonF CF mutations
studied in all the 272 Italian and 86 Czech NonF CF alleles,
3 showed very different frequencies: G551D (qItaly=0.004,
qCzech =0.139; P <10
6); 2183 AA>G ( q Italy =0.081,
qCzech=0.012; P0.03); R1162X (qItaly=0.129, qCzech=
0.00; P5104).
By far the most common of the CF alleles in both
populations is the F508del allele (50% and 70% of the CF
alleles in Italy and in Czech Republic, respectively). Its
exclusive association with the M allele observed in the
present two samples, was already known (e.g. ref. 4;5),
though exceptions were reported [6].Fig. 1. Correlation between the proportion of variable sites where the minor alleleAmong NonF CF mutations, G85E, R553X and N1303K
were found both with the M and the Vallele within the Italian
sample; 1898+1 G>A and 3849+10 Kb C>T were found
both with the M and the V allele within the Czech Republic;
and G551D was found in Italy with the V allele (1/1) and in
the Czech Republic with the M allele (12/12). Thus at least 6
of the 53 NonF CF mutations are certainly associated with
both M and V. All the other 47 CF mutations were associated
with only one of these two alleles: 27 (amounting to a total of
177 CF chromosomes) with the M allele (ref. nos. in Table 1:
4, 5, 7, 8, 9, 11, 14, 15, 16, 18, 20, 23, 24, 25, 26, 27, 28, 31,
32, 33, 35, 40, 42, 43, 44, 45 and 49), and 20 (for a total of 44
CF chromosomes) with the Vallele (ref. nos. 2, 6, 17, 22, 29,
30, 34, 36, 37, 38, 39, 41, 46, 47, 48, 50, 51, 52, 53 and 54),
even though V is more frequent than M (0.615 vs 0.385).
Obviously, however, some of these CFmutations maywell be
associated with both, thus the present ratio of 6/53 is clearly
an underestimate. At any rate, since this source of error
should have affected the M and the V alleles to the same
extent, it makes sense to compare these two alleles even for
the CF mutations detected only once.
The preferential association with the M allele turned out to
be correlated with the distance (hence with the recombination
rate) between the CF mutation and the M470V site (Pone tail =
0.0135, see Fig. 1, Section (a) of the Table). These data allowis only associated with the M allele and their distance from the M470V site.
Fig. 2. Contribution of M/V genotypes to the overall individual risk of being heterozygous for a CF allele in the Italian population.
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variable sites obtained on a sample of random individuals
also to the CF mutations (Fig. 1, Section (b) and (c) of theFig. 3. The partition of the risk of being an Fat risk couple_ amTable) thus strengthening the evidence for a rapid amplifica-
tion of the V allele possibly due to a recent strong selective
advantage favouring the Vallele itself or a variant born in a Vong the 6 possible M/V couples in the Italian population.
Table 4
CF mutations found in the 53 CF patients of the Bolzano province
CF mutation Absolute and relative (%) frequencies Associated with(1)
F508del 56 (52.8) M
711+5 G>A 10 (9.4) M
R347P 3 (2.8) V
S466X 1 (0.9) M
1717-1 G>A 1 (0.9) M
G542X 1 (0.9) M
G551D 2 (1.9) V
1874insT 1 (0.9) V
2183AA>G 3 (2.8) M
2789+5G>A 1 (0.9) M
R1162X 24 (22.6) M
N1303K 2 (1.8) M
(1)Based on data of Table 1.
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beginning of this process, ca. 85% of the variability was
restricted to the M alleles. Then, such proportion decreased
through recombination with an estimated slope equal to
0.007. Since no evidence for the occurrence of an HSR (Hot
Spot of Recombination) in the CFTR gene does exist and
present data also exclude such an occurrence, it appears
reasonable to assume that the Recombination Rate is
uniformly distributed in the here explored region and equal
to the commonly accepted overall mean value of 1 cM=1
Mb. On these bases the estimate of the time 0 is approxi-
mately 1100 generations (25,000 yrs).
4.1. Implication for a prospective screening strategy in
Northern Italy
The strong association between the M allele and the CF
mutations implies that individuals differing for the M/V
genotype have a different risk to be a CF carrier. Figs. 2 andTable 5
Inferred individual and couple risks for the Bolzano province population with tw
Level Frequency (%) One-phase screening strategy
Residual risk after the use of the
CF mutation kita
Individual Equal for all genotypes 0.020.04=8
MM 14.8
MV 47.4
VV 37.8
Couple Equal for all couples (8104)2 ,0
1st class
MMMM 2.2
MMMV 14.0
MVMV 22.4
2nd class
MMVV 11.2
MVVV 35.8
VVVV 14.3
1st and 2nd class couples=couples with a risk higher or, respectively, lower than
a CF mutation detection rate: 98%.
b Bracketed figures are the relative percent contributions to the weighted mean
c Following the use of the CF mutation kit on the 1st class individuals or coup
d Obtained by adding the risk of each type of couple multiplied by the corresp3 compare individuals and couples, respectively, with
different M/V genotypes for their specific risk and for their
contribution to the total risk. For each genotype or couple,
the contribution is the area corresponding to the product of
its frequency (abscissa) by its specific risk (ordinate). A very
good agreement was found for the six types of couples
between their observed proportions and those inferred from
the CF/MV haplotype frequencies (see Table 3). The
specific risk is the value that matters for genetic counselling,
whereas the values relevant for public health are the relative
contributions of the different individual or couple genotypes
to the overall risk. As shown in Fig. 3, the 6 possible types
of couples can be subdivided into two classes: couples in
which both partners have at least one M allele, and the
remaining couples.
First class couples, which amount to the 39% of the total,
have risks ranging from 1.6 and 5.8 fold greater than the
random risk of 16104. Second class couples, 61%, have
risks ranging between one third and one fiftieth of the
weighted mean risk. On this basis, a reasonable prospective
screening option would consist in examining only the 1st
class couples for the CF mutations most common in the area
under study, considering not at risk the 2nd class couples.
4.2. A pilot screening program
The expected results of a pilot screening program as that
here proposed have been computed for the Bolzano
province population (Alto Adige, North East Italy).
All the CF patients of this local population have been
fully characterized (Table 4); the prevalence of the disease
and the M/V allele frequencies have been assumed to be
those observed in other European populations, namely 1/
2500; 0.385 and 0.615. Table 5 shows the estimated residualo different screening strategies
Two-phase screening strategy
1st phase risk (104)
based on the M/V genotypeb
2nd phase residual risksc
104 Weighted mean=400
980 (36.3) 8104
8104508 (60.2)
37 (3.5) 37104
Weighted mean 16 Weighted meand1.18104
96 (13.2) ,0
,0
,0
50 (43.7)
26 (36.2)
4 (2.5) 4x104
2 (4.2) 2x104
0.1 (0.1) 0.1x104
the weighted mean risk (see text).
risk: (percent frequency risk) /weighted mean risk.
les only.
onding frequency: (40.112)+(20.358)+(0.10.143)=1.18.
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strategies at the individual or at the couple level:
(a) the one-phase screening strategy would consist in
examining all individuals or couples with a home-
made kit which detects 98% of the CF mutations. This
strategy would lead to the identification of almost all
the CF carriers and the residual individual risk would
be 8104 (i.e. 2% of 400104, the population
carrier frequency);
(b) the two-phase screening strategy would consist in first
typing all the individuals or couples for the M/V
genotype. This phase would lead to the subdivision of
the general population into classes of individuals or
couples having different risks of being CF carriers or
an at risk couple. The at risk individuals or couples
only would then be examined with the CF mutation
kit in the second phase.
Both strategies would attain a substantially full prospec-
tive prevention of CF. Being almost equal the benefits, the
difference would then depend only on cost: mutation
screening in all individuals vs M470V genotyping in all
individuals and mutation screening in 62% of the individ-
uals, or 39% of the couples.
For the Czech sample, the contribution of the F508del to
the CF total frequency (=0.02) is equal to the 70% (12),
namely to 0.014, and the combined contribution of the four
most common NonF CF mutations (ref. nos. 2, 9, 10 and 21
in Table 1) is half of the residual CF alleles frequency,
namely 0.006/2=0.003. Thus, two options are available:
that of screening for only the F508del and that of screening
also for the other four Fcommon_ CF mutations.
It appears clearly that, at the couple level, the screening
of F508del would be effective enough to reduce more than
tenfold the standard random risk (from 16104 to
1.5104) for the couples where none of the parents
turned out to be heterozygous for that mutation.
The great difference between the strategies convenient
for prospective genetic counselling on Italians vs Czechs
highlights the necessity of a preliminary detailed informa-
tion on the CFTR genetic structure of any population to be
subjected to a general prospective genetic counselling.Acknowledgement
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